Lupin Q1 FY27 Results Analysis: EBITDA Margin Expands 357 bps, Tax Rate Doubles

Lupin Ltd reported Q1 FY27 numbers with revenue of Rs. 8,276.89 Cr (+32.04% YoY) and PAT growth of +16.01% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Lupin delivered a record Q1 with revenue up 32% YoY and EBITDA margin expanding 357 bps to 29.76%, far above the 25% full-year guidance. The only drag was a doubling of the effective tax rate, which compressed PAT growth to 16%. The strong start, driven by US launches, chronic portfolio momentum, and VISUfarma consolidation, positions the company well to exceed its FY27 targets.

Key Investment Insights

Key Positives

• Revenue grew 32.04% YoY to Rs.8,276.89 Cr, the strongest Q1 print in recent history, driven by US business, India chronic momentum, and VISUfarma consolidation.
• EBITDA margin expanded 357 bps YoY to 29.76%, well ahead of management's FY27 guidance of ~25%.
• EBITDA grew ~50% YoY, demonstrating strong operating leverage as revenue grew 32%.
• Zero exceptional items in Q1 FY27, marking the first quarter without Mirabegron settlement impact.
• US business benefited from new product launches (Sugammadex, Diazepam injection, Ranibizumab) and an INR depreciation tailwind of ~9-10%.
• India chronic portfolio tracked ahead of IPM growth of ~13.5%.

Risk Factors

• Effective tax rate more than doubled to 29.76% from 13.71% YoY, compressing PAT growth to 16% despite 50% EBITDA growth.
• Current cash tax rate of 48.8% is unsustainably high, likely reflecting one-time gains at the standalone entity.
• D&A surged 51.46% YoY to Rs.452.85 Cr, driven by acquisition intangibles for VISUfarma and Renascience.
• Finance costs increased 19.5% YoY due to incremental debt drawn for the VISUfarma acquisition.
• Consolidated PAT of Rs.1,415 Cr was Rs.1,299.60 Cr lower than standalone PAT, indicating subsidiaries are a net drag on profitability.